JP2019500328A - Ntrkに関連する障害の治療のために有用な化合物及び組成物 - Google Patents

Ntrkに関連する障害の治療のために有用な化合物及び組成物 Download PDF

Info

Publication number
JP2019500328A
JP2019500328A JP2018525688A JP2018525688A JP2019500328A JP 2019500328 A JP2019500328 A JP 2019500328A JP 2018525688 A JP2018525688 A JP 2018525688A JP 2018525688 A JP2018525688 A JP 2018525688A JP 2019500328 A JP2019500328 A JP 2019500328A
Authority
JP
Japan
Prior art keywords
alkyl
heterocyclyl
heteroalkyl
hydroxyalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018525688A
Other languages
English (en)
Japanese (ja)
Inventor
スティーブン マーク ウェングロウスキー,
スティーブン マーク ウェングロウスキー,
チャンドラセカール ブイ. ミドゥトゥル,
チャンドラセカール ブイ. ミドゥトゥル,
ニール ジュニア ビフルコ,
ニール ジュニア ビフルコ,
ジョセフ エル. キム,
ジョセフ エル. キム,
Original Assignee
ブループリント メディシンズ コーポレイション
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション, ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2019500328A publication Critical patent/JP2019500328A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018525688A 2015-11-19 2016-11-18 Ntrkに関連する障害の治療のために有用な化合物及び組成物 Ceased JP2019500328A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257476P 2015-11-19 2015-11-19
US62/257,476 2015-11-19
PCT/US2016/062731 WO2017087778A1 (en) 2015-11-19 2016-11-18 Compounds and compositions useful for treating disorders related to ntrk

Publications (1)

Publication Number Publication Date
JP2019500328A true JP2019500328A (ja) 2019-01-10

Family

ID=57517997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525688A Ceased JP2019500328A (ja) 2015-11-19 2016-11-18 Ntrkに関連する障害の治療のために有用な化合物及び組成物

Country Status (18)

Country Link
US (2) US10370379B2 (cg-RX-API-DMAC7.html)
EP (1) EP3377497A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019500328A (cg-RX-API-DMAC7.html)
KR (1) KR20180081790A (cg-RX-API-DMAC7.html)
CN (1) CN108431008A (cg-RX-API-DMAC7.html)
AR (1) AR106756A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016355196A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018010024A8 (cg-RX-API-DMAC7.html)
CA (1) CA3005741A1 (cg-RX-API-DMAC7.html)
HK (1) HK1259453A1 (cg-RX-API-DMAC7.html)
IL (1) IL259164A (cg-RX-API-DMAC7.html)
MX (1) MX2018006195A (cg-RX-API-DMAC7.html)
PH (1) PH12018501065A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018122089A (cg-RX-API-DMAC7.html)
SG (2) SG10201912607SA (cg-RX-API-DMAC7.html)
TW (1) TWI733713B (cg-RX-API-DMAC7.html)
WO (1) WO2017087778A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803530B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504866A (ja) * 2019-12-13 2023-02-07 ▲賽▼▲諾▼哈勃▲薬▼▲業▼(成都)有限公司 大環構造を有するフッ素含有複素環誘導体およびその用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
KR20250174699A (ko) 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
HUE064283T2 (hu) 2019-04-12 2024-02-28 Blueprint Medicines Corp Az (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il) piperazinil)-pirimidin-5-il)etán-1-amin kristályos formái és elõállítási eljárásai
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业(成都)有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507446A (ja) * 2003-10-03 2007-03-29 エフ.ホフマン−ラ ロシュ アーゲー ピラゾロ及びイミダゾ−ピリミジン誘導体
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2013537199A (ja) * 2010-09-09 2013-09-30 アイアールエム・リミテッド・ライアビリティ・カンパニー Trk阻害薬としてのイミダゾ[1,2]ピリダジン化合物および組成物
WO2014139326A1 (en) * 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
WO2015157093A1 (en) * 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5251911A (en) 1992-12-09 1993-10-12 Blake Carlton E Safety construction for passenger vehicle
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
RU2380369C9 (ru) * 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2010352577A1 (en) 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
CN102241678B (zh) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US20150218652A1 (en) 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) * 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9556181B2 (en) 2013-02-01 2017-01-31 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
KR102148681B1 (ko) * 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108328A1 (ko) * 2014-01-14 2015-07-23 주식회사 엘지생명과학 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE067779T2 (hu) 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3259264B1 (en) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507446A (ja) * 2003-10-03 2007-03-29 エフ.ホフマン−ラ ロシュ アーゲー ピラゾロ及びイミダゾ−ピリミジン誘導体
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2013537199A (ja) * 2010-09-09 2013-09-30 アイアールエム・リミテッド・ライアビリティ・カンパニー Trk阻害薬としてのイミダゾ[1,2]ピリダジン化合物および組成物
WO2014139326A1 (en) * 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
WO2015157093A1 (en) * 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOWLING, JAMES E. ETAL.: "Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization", ACS MEDICINAL CHEMISTRY LETTERS, vol. 3(4),, JPN6020043057, 2012, pages 278 - 283, ISSN: 0004383858 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504866A (ja) * 2019-12-13 2023-02-07 ▲賽▼▲諾▼哈勃▲薬▼▲業▼(成都)有限公司 大環構造を有するフッ素含有複素環誘導体およびその用途

Also Published As

Publication number Publication date
RU2018122089A (ru) 2019-12-25
TWI733713B (zh) 2021-07-21
US20170145018A1 (en) 2017-05-25
TW201720826A (zh) 2017-06-16
CN108431008A (zh) 2018-08-21
KR20180081790A (ko) 2018-07-17
BR112018010024A2 (pt) 2018-11-21
MX2018006195A (es) 2018-09-05
SG10201912607SA (en) 2020-02-27
ZA201803530B (en) 2021-08-25
SG11201803920TA (en) 2018-06-28
PH12018501065A1 (en) 2019-01-28
WO2017087778A1 (en) 2017-05-26
BR112018010024A8 (pt) 2019-02-26
US11059827B2 (en) 2021-07-13
AR106756A1 (es) 2018-02-14
CA3005741A1 (en) 2017-05-26
RU2018122089A3 (cg-RX-API-DMAC7.html) 2019-12-30
HK1259453A1 (zh) 2019-11-29
EP3377497A1 (en) 2018-09-26
IL259164A (en) 2018-06-28
AU2016355196A1 (en) 2018-06-21
US10370379B2 (en) 2019-08-06
US20190382410A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US11059827B2 (en) Compounds and compositions useful for treating disorders related to NTRK
JP7026196B2 (ja) Retの阻害剤
US11046697B2 (en) Compounds and compositions useful for treating disorders related to NTRK
WO2021088945A1 (zh) 作为shp2抑制剂的化合物及其应用
HK1255103A1 (zh) 可用於治疗与kit和pdgfr相关的病症的化合物
US20200024280A1 (en) Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
HK40105122A (en) Inhibitors of ret

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20211130